Aliases & Classifications for Melanoma

About this section

Aliases & Descriptions for Melanoma:

Name: Melanoma 11 13 25 48 36 37 66
Malignant Melanoma 11 25
 
Cutaneous Melanoma 66
Naevocarcinoma 11

Classifications:



External Ids:

Disease Ontology11 DOID:1909
MeSH37 D008545
NCIt43 C3224
ICD1028 D03.9

Summaries for Melanoma

About this section
MedlinePlus:36 Melanoma is the most serious type of skin cancer. often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. most melanomas have a black or black-blue area. melanoma may also appear as a new mole. it may be black, abnormal, or "ugly looking." thinking of "abcde" can help you remember what to watch for: asymmetry - the shape of one half does not match the other border - the edges are ragged, blurred or irregular color - the color is uneven and may include shades of black, brown and tan diameter - there is a change in size, usually an increase evolving - the mole has changed over the past few weeks or months surgery is the first treatment of all stages of melanoma. other treatments include chemotherapy and radiation, biologic, and targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary: Melanoma, also known as malignant melanoma, is related to ciliary body spindle cell melanoma and learning disability, and has symptoms including exanthema, exanthema and pruritus. An important gene associated with Melanoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways is Senescence and Autophagy. The drugs temozolomide and carmustine have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and brain, and related mouse phenotype pigmentation.

Disease Ontology:11 A cell type cancer that has material basis in abnormally proliferating cells derived from melanocytes which are found in skin, the bowel and the eye.

Novus Biologicals:49 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

Wikipedia:69 Melanoma, also known as malignant melanoma, is a type of cancer that develops from the... more...

Related Diseases for Melanoma

About this section

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 670)
idRelated DiseaseScoreTop Affiliating Genes
1ciliary body spindle cell melanoma33.9CDKN2A, MIA, MITF, MLANA
2learning disability30.2BRAF, CDKN2A, MIA, MITF
3malignant melanoma, somatic12.3
4skin melanoma12.3
5ocular melanoma12.2
6uveal melanoma12.2
7acral lentiginous melanoma12.2
8amelanotic melanoma12.1
9nodular malignant melanoma12.1
10melanoma and neural system tumor syndrome12.0
11mucosal melanoma12.0
12lentigo maligna melanoma12.0
13melanoma, cutaneous malignant 812.0
14malignant spindle cell melanoma12.0
15pancreatic cancer/melanoma syndrome12.0
16superficial spreading melanoma12.0
17posterior uveal melanoma12.0
18melanoma-associated retinopathy12.0
19digestive system melanoma12.0
20melanoma, cutaneous malignant, 912.0
21melanoma, cutaneous malignant, 211.9
22melanoma, cutaneous malignant, 311.9
23melanoma, cutaneous malignant, 611.9
24melanoma, cutaneous malignant, 511.9
25vulvar melanoma11.9
26meningeal melanoma11.9
27spinal cord melanoma11.9
28gallbladder melanoma11.9
29epithelioid cell melanoma11.9
30malignant choroid melanoma11.9
31malignant iris melanoma11.9
32choroid spindle cell melanoma11.9
33primary malignant melanoma of the cervix11.9
34balloon cell malignant melanoma11.9
35orbital melanoma11.9
36melanoma metastasis11.9
37iris spindle cell melanoma11.9
38ovarian melanoma11.8
39melanoma, cutaneous malignant 1011.8
40necrotic uveal melanoma11.8
41malignant eyelid melanoma11.8
42malignant conjunctiva melanoma11.8
43primary melanoma of the central nervous system11.8
44malignant anus melanoma11.8
45melanoma of soft tissue11.8
46cervix melanoma11.8
47malignant breast melanoma11.8
48malignant ciliary body melanoma11.8
49malignant cornea melanoma11.8
50melanoma, uveal 211.7

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to melanoma

Symptoms for Melanoma

About this section

UMLS symptoms related to Melanoma:


exanthema, pruritus

Drugs & Therapeutics for Melanoma

About this section

FDA approved drugs:

(show all 12)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Erivedge16 42 VISMODEGIB Genentech January 2012
FDA Label: Erivedge
Disease/s that Drug Treats:basal cell carcinoma
Indications and Usage:16 ERIVEDGE (vismodegib) capsule is a hedgehog pathway inhibitor indicatedfor the treatment of adults with metastatic basal cell carcinoma, or with locallyadvanced basal cell carcinoma that has recurred following surgery or who arenot candidates for surgery, and who are not candidates for radiation. (1)
DrugBank Targets:14 1. Smoothened homolog
Mechanism of Action:16 
Target: hedgehog (Hh) signaling pathway
Action: innhibitor
FDA: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibitsSmoothened, a transmembrane protein involved in Hedgehog signal transduction.
2
Intron A16 42 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:16 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:14 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:16 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Keytruda16 42 PEMBROLIZUMAB Merck September 2014
FDA Label: Keytruda
Disease/s that Drug Treats:unresectable or metastatic melanoma
Indications and Usage:16 KEYTRUDA is a human programmed death receptor-1 (PD-1)-blockingantibody indicated for the treatment of patients with unresectable ormetastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumorresponse rate and durability of response. An improvement in survivalor disease-related symptoms has not yet been established. Continuedapproval for this indication may be contingent upon verification anddescription of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:14 1. Programmed cell death protein 1
Mechanism of Action:16 
Target: PD-1 receptor
Action: blocks interaction withPD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cellproliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction withPD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including theanti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted indecreased tumor growth.
4
Mekinist16 42 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
FDA Label: Mekinist
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E or V600K mutations
Indications and Usage:16 MEKINIST is a kinase inhibitor indicated as a single agent and incombination with dabrafenib for the treatment of patients with unresectable ormetastatic melanoma with BRAF V600E or V600K mutations as detected byan FDA-approved test. The use in combination is based on the demonstrationof durable response rate. Improvement in disease-related symptoms or overallsurvival has not been demonstrated for MEKINIST in combination withdabrafenib. (1, 14.1)Limitation of use: MEKINIST as a single agent is not indicated for treatmentof patients who have received prior BRAF-inhibitor therapy. (1)
DrugBank Targets:14 1. Dual specificity mitogen-activated protein kinase kinase 1;2. Dual specificity mitogen-activated protein kinase kinase 2
Mechanism of Action:16 
Target: mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase
Action: inhibitor
FDA: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1(MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins areupstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotescellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAFpathway which includes MEK1 and MEK2. Trametinib inhibits BRAF V600 mutation-positivemelanoma cell growth in vitro and in vivo.Trametinib and dabrafenib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
5
Odomzo16 42 SONIDEGIB PHOSPHATE Novartis Jul-15
FDA Label: Odomzo
Disease/s that Drug Treats:locally advanced basal cell carcinoma
Indications and Usage:16 ODOMZO is a hedgehog pathway inhibitor indicated for the treatment ofadult patients with locally advanced basal cell carcinoma (BCC) that hasrecurred following surgery or radiation therapy, or those who are notcandidates for surgery or radiation therapy. (1)
DrugBank Targets: -
Mechanism of Action:16 
Target: Smoothened
Action: inhibitor
FDA: Sonidegib is an inhibitor of the Hedgehog pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane proteininvolved in Hedgehog signal transduction.
6
Opdivo16 42 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer/ unresectable or metastatic melanoma
Indications and Usage:16 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibodyindicated for the treatment of patients with: unresectable or metastatic melanoma and disease progression followingipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1)This indication is approved under accelerated approval based on tumorresponse rate and durability of response. Continued approval for thisindication may be contingent upon verification and description of clinicalbenefit in the confirmatory trials. (1.1, 14.1) metastatic squamous non-small cell lung cancer with progression on orafter platinum-based chemotherapy. (1.2)
DrugBank Targets:14 1. Programmed cell death protein 1
Mechanism of Action:16 
Target: PD-1 receptor
Action: blocker of interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibitsT-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in sometumors and signaling through this pathway can contribute to inhibition of active T-cell immunesurveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibodythat binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1pathway-mediated inhibition of the immune response, including the anti-tumor immuneresponse. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumorgrowth.
7
Proleukin16 42 ALDESLEUKIN Chiron January 1998
FDA Label: Proleukin
Disease/s that Drug Treats:Metastatic melanoma
Indications and Usage:16 Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cellcarcinoma (metastatic RCC).Proleukin is indicated for the treatment of adults with metastatic melanoma.Careful patient selection is mandatory prior to the administration of Proleukin. See“CONTRAINDICATIONS”, “WARNINGS” and “PRECAUTIONS” sections regarding patientscreening, including recommended cardiac and pulmonary function tests and laboratorytests.Evaluation of clinical studies to date reveals that patients with more favorable ECOGperformance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with ahigher response rate and lower toxicity (See “CLINICAL PHARMACOLOGY” section,“CLINICAL STUDIES” section and “ADVERSE REACTIONS” section). Therefore, selectionof patients for treatment should include assessment of performance status.Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:14 1. Interleukin-2 receptor subunit beta;2. Interleukin-2 receptor subunit alpha;3. Cytokine receptor common subunit gamma
Mechanism of Action:16 
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocytemitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human nativeinterleukin-2.1,2 In vitro studies performed on human cell lines demonstrate theimmunoregulatory properties of Proleukin, including: a) enhancement of lymphocytemitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated(LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.The in vivo administration of Proleukin in animals and humans produces multipleimmunological effects in a dose dependent manner. These effects include activation ofcellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and theproduction of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivoexperiments in murine tumor models have shown inhibition of tumor growth.4 The exactmechanism by which Proleukin mediates its antitumor activity in animals and humans isunknown.
8
Sylatron16 42 PEGINTERFERON ALFA-2B Merck April 2011
FDA Label: Sylatron
Disease/s that Drug Treats:melanoma
Indications and Usage:16 PegIntron is an antiviral indicated for treatment of Chronic Hepatitis C(CHC) in patients with compensated liver disease. (1.1)
DrugBank Targets:14 1. Interferon alpha/beta receptor 1;2. Interferon alpha/beta receptor 2
Mechanism of Action:16 
Target: innate antiviral immune response
Action: inducer
FDA: Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response [see Microbiology (12.4)].
9
Tafinlar16 42 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
FDA Label: Tafinlar
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E mutation
Indications and Usage:16  TAFINLAR is a kinase inhibitor indicated as a single agent for thetreatment of patients with unresectable or metastatic melanoma withBRAF V600E mutation as detected by an FDA-approved test. (1.1, 2.1) TAFINLAR in combination with trametinib is indicated for the treatmentof patients with unresectable or metastatic melanoma with BRAF V600Eor V600K mutations as detected by an FDA-approved test. The use incombination is based on the demonstration of durable response rate.Improvement in disease-related symptoms or overall survival has notbeen demonstrated for TAFINLAR in combination with trametinib. (1.2,2.1, 14.2)Limitation of Use: TAFINLAR is not indicated for treatment of patients withwild-type BRAF melanoma. (1.3, 5.2)
DrugBank Targets:14 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Serine/threonine-protein kinase SIK1;4. Serine/threonine-protein kinase Nek11;5. LIM domain kinase 1
Mechanism of Action:16 
Target: some mutated forms of BRAF kinases, wild-type BRAF and CRAF kinases
Action: inhibitor
FDA: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes,respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higherconcentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E,can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [seeIndications and Usage (1)]. Dabrafenib inhibits BRAF V600 mutation-positive melanoma cellgrowth in vitro and in vivo.Dabrafenib and trametinib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
10
Yervoy16 42 IPILIMUMAB Bristol-Myers Squibb March 2011
FDA Label: Yervoy
Disease/s that Drug Treats:metastatic melanoma
Indications and Usage:16 YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blockingantibody indicated for the treatment of unresectable or metastaticmelanoma. (1)
DrugBank Targets:14 1. Cytotoxic T-lymphocyte protein 4
Mechanism of Action:16 
Target: CTLA-4
Action: blocker of interation with CD80/CD86
FDA: CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody thatbinds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockadeof CTLA-4 has been shown to augment T-cell activation and proliferation, including theactivation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signalingcan also reduce T-regulatory cell function, which may contribute to a general increase in T cellresponsiveness, including the anti-tumor immune response.
11
Zelboraf16 42 VEMURAFENIB Roche August of 2011
FDA Label: Zelboraf
Disease/s that Drug Treats:BRAF + melanoma
Indications and Usage:16 ZELBORAF® is a kinase inhibitor indicated for the treatment of patients withunresectable or metastatic melanoma with BRAF V600E mutation as detectedby an FDA-approved test. (1, 2.1)Limitation of Use: ZELBORAF is not indicated for treatment of patients withwild-type BRAF melanoma. (2.1, 5.2)
DrugBank Targets:14 1. Serine/threonine-protein kinase B-raf
Mechanism of Action:16 
Target: some mutated forms of BRAF serinethreoninekinase
Action: inhibitor
FDA: Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serinethreoninekinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF,ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in theBRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cellproliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenibhas anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E.
12
Opdivo16 NIVOLUMAB Bristol-Myers Squibb March 2015
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:16 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with: * unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.1, 14.1) * metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. (1.2)
DrugBank Targets:14 Programmed cell death protein 1
Mechanism of Action:16 
Target: PD-1 receptor
Action: blocks its interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 321)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
LapatinibApproved March 2007Phase 4, Phase 2296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
2triamcinolone acetonidePhase 4, Phase 2, Phase 3463
3
RanibizumabPhase 4, Phase 3, Phase 2, Phase 1469347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
4
TriamcinolonePhase 4, Phase 2, Phase 3463124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
5glucocorticoidsPhase 4, Phase 2, Phase 3, Phase 14756
6
sirolimusPhase 4, Phase 2, Phase 1186353123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
7
BortezomibPhase 4, Phase 2, Phase 1783179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
8
ramucirumabPhase 4, Phase 2, Phase 168947687-13-0
Synonyms:
IMC-1121B
 
IMC-3G3
ramucirumab
9
MiconazolePhase 4, Phase 2, Phase 1357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
10Imatinib MesylatePhase 4, Phase 2, Phase 1588123596
11
EverolimusPhase 4, Phase 2, Phase 11863159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
12
erlotinib hydrochloridePhase 4, Phase 3, Phase 2, Phase 1793183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
13
OlaparibPhase 4, Phase 1117763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
14
DasatinibPhase 4, Phase 2, Phase 1276302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
15
SorafenibPhase 4, Phase 3, Phase 2, Phase 1681284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
16
TrametinibPhase 4, Phase 3, Phase 2, Phase 1115871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
17
ImiquimodPhase 4, Phase 3, Phase 2, Phase 113599011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
18interferonsPhase 4, Phase 3, Phase 2, Phase 1, Phase 02112
19
SerotoninPhase 4, Phase 1, Phase 2351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
20INTERLEUKIN-2Phase 4, Phase 3, Phase 2, Phase 1, Phase 0537
21
CitalopramPhase 450059729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
22dexetimidePhase 450021888-98-2
23
nivolumabPhase 4, Phase 2, Phase 3, Phase 1254946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
24
CisplatinPhase 4, Phase 3, Phase 1, Phase 2261415663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
25
VorinostatPhase 4, Phase 2, Phase 1240149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
26
Edetic AcidPhase 4, Phase 3, Phase 28960-00-4, 62-33-96049
Synonyms:
(ethylenedinitrilo)tetraacetic acid, ion(4−)
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcium Disodium Edetate (JAN)
Calcium Disodium Versenate
Calcium disodium versenate (TN)
 
EDT
EDTA
EDTA, ion(4-)
Edetate Calcium
Edetate calcium disodium (USP)
Ethylenediaminetetraacetate
Ethylenediaminetetraacetic acid
N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
acide edetique
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
27
AldesleukinPhase 4, Phase 3, Phase 2, Phase 1, Phase 039185898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
28
EtanerceptPhase 4391185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
29
DacarbazinePhase 4, Phase 3, Phase 2, Phase 16514342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
30
SunitinibPhase 4, Phase 2, Phase 1493341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
31
PalbociclibPhase 4, Phase 1, Phase 2107571190-30-211431660, 5005498
Synonyms:
2euf
571190-30-2
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
 
EC-000.2350
Kinome_3823
Kinome_3824
LQQ
PD 0332991
PD 332991, PD 0332991, PD0332991
PD-0332991
PD-332991
PD0332991
Palbociclib
S1116_Selleck
32
BupropionPhase 431334841-39-9, 34911-55-2444
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
AMFEBUTAMONE HCl
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion Hcl
Bupropion SR
Bupropion [INN:BAN]
Bupropion hydrocloride
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
 
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
LS-122817
Lopac0_000166
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
Spectrum_001663
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
alpha-(tert-butylamino)-m-chloropropiophenone
amfebutamonum
bupropion
33
Technetium tc 99m sulfur colloidPhase 4, Phase 121
Synonyms:
 
Technetium 99m sulfur colloid
Technetium Tc-99m Sulfur Colloid
34
Aminolevulinic acidPhase 4, Phase 2150106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
35
lactitolPhase 4, Phase 1, Phase 2325585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
36
NicotinePhase 4101654-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+-)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(R,S)-nicotine
(RS)-nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(±)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
37
VindesinePhase 44359917-39-4, 53643-48-440839
Synonyms:
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
AC1L24KY
C43H55N5O7
CHEBI:36373
CHEMBL219146
CID40839
D06304
DAVA
DB00309
Desacetylvinblastine Amide Sulfate
Desacetylvinblastine amide
EINECS 258-682-2
Eldesine
Eldisine
 
HMS2090E15
HSDB 6961
LS-162145
Lilly 112531
MolPort-005-933-570
NSC-245467
STOCK1N-75293
UNII-RSA8KO39WH
Vindesin
Vindesina
Vindesina [INN-Spanish]
Vindesine (USAN/INN)
Vindesine Sulfate
Vindesine [USAN:BAN:INN]
Vindesine [USAN:INN:BAN]
Vindesinum
Vindesinum [INN-Latin]
methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
vindesine
38
VareniclinePhase 4263249296-44-45310966
Synonyms:
249296-44-4
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine
7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
AC1L55H0
AC1Q4W6H
AKOS005145561
AR-1H2911
CHEBI:430452
CHEMBL1396
CID170361
CP 526555
 
CP-526,555
Champix
Chantix
D08669
HSDB 7591
I14-1963
LS-187375
UNII-W6HS99O8ZO
Varenicline
Varenicline (INN)
Varenicline tartrate
varenicline
39
CrizotinibPhase 4, Phase 297877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
40
ceritinibPhase 4, Phase 2, Phase 0361032900-25-6
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
LDK378
 
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
céritinib
41
GefitinibPhase 4345184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
42
AlefaceptPhase 440222535-22-0
Synonyms:
 
ASP0485
43
SufentanilPhase 316656030-54-741693
Synonyms:
56030-54-7
60561-17-3 (citrate)
AC1L26AJ
AC1Q5I7B
C08022
C22H30N2O2S
CHEBI:127638
CHEBI:9316
CHEMBL658
CID41693
Chronogesic
D05938
DB00708
HSDB 6760
L000580
LS-175693
MolPort-004-286-008
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
 
N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
Oprea1_120838
Oprea1_246787
PDSP1_001741
PDSP2_001724
R 30730
R-30730
SUFENTANIL
Sufentanil
Sufentanil (USAN/INN)
Sufentanil Citrate
Sufentanil [USAN:BAN:INN]
Sufentanilo
Sufentanilum
Sufentanilum [INN-Latin]
Sufentanyl
Sulfentanil
Sulfentanyl
UNII-AFE2YW0IIZ
44
RopivacainePhase 370984057-95-471273, 175805
Synonyms:
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
(S)-(−)-1-propyl-2',6'-pipecoloxylidide
(S)-ropivacaine
84057-95-4
98717-15-8
AC1L41QM
AC1L41QN
BIDD:GT0203
C07532
C17H26N2O.HCl
CHEBI:8890
CHEMBL1077896
CID175804
CID175805
CPD000469137
D08490
I14-176
L-N-n-propylpipecolic acid-2,6-xylidide
LS-113954
 
MLS001401363
MolPort-003-983-292
NCGC00164597-01
Naropin
Naropin (TN)
ROPIVACAINE HCl
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
SAM001246524
SMR000469137
ST51051452
ropivacaine monohydrochloride,
ropivacaine monohydrochloride, (S)-isomer
45
DiphenoxylatePhase 34915-30-013505
Synonyms:
1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester
1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester
1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride
1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride
2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile
3810-80-8
3810-80-8 (mono-hydrochloride)
4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile
4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride
4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester
4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI)
4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride
4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride
5-22-02-00487 (Beilstein Handbook Reference)
915-30-0
915-30-0 (Parent)
AC1L21V6
AC1L2EKB
AC1O5E7B
AC1Q1SJB
AC1Q4QOH
AKOS005065925
BRN 0503374
C07872
C30H32N2O2
C30H32N2O2.HCl
CHEBI:59784
CHEMBL1200665
CID13505
CID19650
CID6432394
CPD000469140
D03860
D07861
DB01081
DEA No. 9170
DIPHENOXYLATE
Dea No. 9170
Difenossilato
Difenossilato [DCIT]
 
Difenossilato [Dcit]
Difenoxilato
Difenoxilato [INN-Spanish]
Difenoxilato [Spanish]
Diphenoxalate
Diphenoxylate (INN)
Diphenoxylate HCl
Diphenoxylate Monohydrochloride
Diphenoxylate [INN:BAN]
Diphenoxylate hydrochloride
Diphenoxylate hydrochloride (USP)
Diphenoxylatum
Diphenoxylatum [INN-Latin]
Diphenoxylatum [Latin]
EINECS 213-020-1
EINECS 223-287-6
Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate
Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate
Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride
FT-0080160
HSDB 3067
Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester
Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride
L001046
LS-85078
LS-85079
MLS001401383
MolPort-004-285-933
NCGC00167963-01
NIH 7562
R 1132
R 1132 (antiperistaltic)
R-1132
SAM001246532
SMR000469140
UNII-73312P173G
UNII-W24OD7YW48
diphenoxylate hydrochloride(usp)
ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride
ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride
46
LoperamidePhase 314053179-11-63955
Synonyms:
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6
AB00053697
AC1L1H38
AKOS000573892
Apo-Loperamide
BAS 01889668
BPBio1_000274
BRD-K61250553-001-02-9
BRD-K61250553-003-05-8
BRN 1558273
BSPBio_000248
BSPBio_001381
BSPBio_002769
Bio1_000082
Bio1_000571
Bio1_001060
Bio2_000101
Bio2_000581
C07080
C29H33ClN2O2
CAS-34552-83-5
CBiol_001796
CHEBI:162259
CHEBI:6532
CHEMBL841
CID3955
D08144
DB00836
Diamide (TN)
Diarr-Eze
DivK1c_000215
EINECS 258-416-5
HMS1791F03
HMS1989F03
HMS2089C13
IDI1_000215
IDI1_033851
Imodium A-D
Imodium A-D Caplets
Ioperamide
KBio1_000215
KBio2_000101
KBio2_000854
KBio2_002669
KBio2_003422
KBio2_005237
KBio2_005990
KBio3_000201
 
KBio3_000202
KBio3_001989
KBioGR_000101
KBioGR_001685
KBioSS_000101
KBioSS_000854
Kaopectate II
L000709
LS-114352
Lopac-L-4762
Lopac0_000708
Loperacap
Loperamid
Loperamida
Loperamida [INN-Spanish]
Loperamide (INN)
Loperamide Monohydrochloride
Loperamide [INN:BAN]
Loperamide hydrochloride
Loperamidum
Loperamidum [INN-Latin]
Lopéramide
Maalox Anti-Diarrheal
MolPort-001-969-016
NCGC00015608-01
NCGC00015608-08
NCGC00016828-01
NCGC00024818-01
NCGC00024818-02
NCGC00024818-03
NCGC00024818-04
NCGC00024818-05
NINDS_000215
Nu-Loperamide
Oprea1_109220
PMS-Loperamide
Pepto Diarrhea Control
Prestwick0_000144
Prestwick1_000144
Prestwick2_000144
Prestwick3_000144
R-18553
Rho-Loperamide
SPBio_001816
SPBio_002187
ST095179
Spectrum2_001738
Spectrum3_001015
Spectrum4_001143
Spectrum5_001374
Spectrum_000374
Tocris-0840
UNII-6X9OC3H4II
loperamide
nchembio.559-comp8
nchembio.79-comp7
47
EpinephrinePhase 388651-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
48
AtropinePhase 31205908-99-6, 51-55-8174174
Synonyms:
(+,-)-Tropyl tropate
(+-)-Atropine
(+-)-Hyoscyamine
(+-)-atropine
(+-)-hyoscyamine
(+/-)-Atropine
(+/-)-Hyoscyamine
(3-Endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
(3-endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
(3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[3.2.1]octane
(3-exo)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
(±)-atropine
(±)-hyoscyamine
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester)
1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI)
120-29-6
1alphaH,5alphaH-Tropan-3alpha-ol
1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester)
1alphaH,5alphaH-Tropan-3beta-ol
2-Phenylhydracrylic acid 3-alpha-tropanyl ester
51-55-8
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate
8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate
8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropionate
A0132_SIGMA
A2468_SIGMA
AC1L5AX3
AC1Q3XL2
ACon1_000046
AI3-60219
AKOS005137976
ATROPINE
Ambap120-29-6
Anaspaz
Atropair
Atropen
Atropen (TN)
Atropin
Atropin [German]
Atropin-flexiolen
Atropina
Atropina [Italian]
Atropine
Atropine (USP)
Atropine Care
Atropine Sulfate
Atropine Sulfate S.O.P.
Atropine [BAN]
Atropinol
Atropinum
Atropt
Atrosulf
BRD-A27290375-001-01-8
Belladenal
Bellergal-S
Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester
C01479
C17H23NO3
CAS-120-29-6
CCRIS 3080
CHEBI:15742
CHEBI:15884
CHEBI:16684
CHEBI:537621
CHEBI:57858
CHEMBL1235490
 
CID174174
CPD001906768
Cytospaz
D00113
DB00572
DB04026
DL-Hyoscyamine
DL-Tropanyl 2-hydroxy-1-phenylpropionate
DL-Tropyl tropate
EINECS 200-104-8
Eyesules
FT-0082634
HMS2089A16
HSDB 2199
Hyoscyamine sulfate
I-Tropine
Isopto Atropine
Isopto-atropine
LS-7203
MEGxp0_001878
MLS000069795
MLS001148094
MLS002695888
Minims
Minims Atropine
MolPort-001-742-593
MolPort-003-986-158
Mydriasine
NCGC00016370-01
NCGC00142514-01
NCGC00142514-03
NP-010662
Neo-Diophen
OR22908
Ocu-Tropine
Protamine & Atropine
SAM002554885
SMR000058248
ST057178
ST057655
T0534
TL8000018
Tropanol
Tropic acid, 3-alpha-tropanyl ester
Tropic acid, ester with tropine
Tropine (+/-)-tropate
Tropine tropate
Tropine, tropate (ester)
Troyl tropate
Urised
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
[(1S,5R)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 3-hydroxy-2-phenyl-propanoate
a-Tropine
atropinium cation
atropinium(1+)
b eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]
beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]
bmse000649
d1-hyoscyamine
dl-Hyoscyamine
dl-Tropyltropate
dl-tropyltropate
endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
endo-8-methyl-8-azabicyclo[3.2.1]octan-3-ol
hyoscyamine
nchembio.307-comp21
tropan-3alpha-ol
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate
tropan-3beta-ol
49Dopamine agonistsPhase 3611
50
HydrocortisonePhase 3, Phase 260250-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone

Interventional clinical trials:

(show top 50)    (show all 2012)
idNameStatusNCT IDPhase
1Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal MelanomaCompletedNCT01253759Phase 4
2Can We Miss Pigmented Lesions in Psoriasis Patients?CompletedNCT01053819Phase 4
3Post-Operative Drainage Following Lymph Node DissectionCompletedNCT00324272Phase 4
4Surgery Versus Radiosurgery to Treat Metastatic Brain TumorsCompletedNCT00075166Phase 4
5Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 TreatmentCompletedNCT00352885Phase 4
6A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node DissectionCompletedNCT02476357Phase 4
7Effect of Topical Imiquimod on Lentigo MalignaCompletedNCT01161888Phase 4
8Characterization of the Melanoma-Specific Immune ResponseRecruitingNCT00368615Phase 4
9Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesRecruitingNCT02626065Phase 4
10Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant MelanomaRecruitingNCT00226473Phase 4
11Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll MelanomaRecruitingNCT02451488Phase 4
12Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
13Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing CreamRecruitingNCT02685592Phase 4
14Sentinel Lymph Node Biopsy Findings in Patients With Breast CancerRecruitingNCT02287675Phase 4
15Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness TrialRecruitingNCT01871506Phase 4
16A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.Active, not recruitingNCT02068196Phase 4
17TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam TherapyActive, not recruitingNCT02379000Phase 4
18An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic MelanomaActive, not recruitingNCT01898585Phase 4
19Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque RadiotherapyActive, not recruitingNCT00540930Phase 4
20Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaNot yet recruitingNCT02645149Phase 4
21Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic InfectionNot yet recruitingNCT02910557Phase 4
22HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic MelanomaTerminatedNCT01683188Phase 4
23HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4
24Assessment and Tracking of Long-term Alefacept SafetyTerminatedNCT00454701Phase 4
25Genetically-informed Therapies for Patients With Metastatic CancerWithdrawnNCT02000739Phase 4
26MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3
27Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003647Phase 3
28Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With MelanomaCompletedNCT00002882Phase 3
29Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to MelanomaCompletedNCT00324727Phase 3
30Multicenter Selective Lymphadenectomy Trial (MSLT)CompletedNCT00275496Phase 3
31Nordic Adjuvant IFN Melanoma TrialCompletedNCT01259934Phase 3
32A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaCompletedNCT00864253Phase 3
33Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedNCT00769704Phase 3
34Trial of Dacarbazine With or Without Genasense in Advanced MelanomaCompletedNCT00518895Phase 3
35Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent MelanomaCompletedNCT00002892Phase 3
36Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV MelanomaCompletedNCT00072124Phase 3
37Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the GroinCompletedNCT00003444Phase 3
38S0008: Chemotherapy Plus Biological Therapy in Treating Patients With MelanomaCompletedNCT00006237Phase 3
39Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced MelanomaCompletedNCT01989572Phase 3
40Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node MetastasisCompletedNCT00004196Phase 3
41Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant MelanomaCompletedNCT00016263Phase 3
42A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 MelanomaCompletedNCT00395070Phase 3
43Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaCompletedNCT00055562Phase 2, Phase 3
44Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic MelanomaCompletedNCT00003027Phase 3
45Breast and Melanoma Trial With Lymphoseek to Identify Lymph NodesCompletedNCT01106040Phase 3
46An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedNCT01368276Phase 3
47Tumor Infiltrating Lymphocytes Adjuvant Therapy of MelanomaCompletedNCT00200577Phase 3
48Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal MelanomaCompletedNCT00680225Phase 3
49Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)CompletedNCT00091572Phase 3
50Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph NodesCompletedNCT00287196Phase 3

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

About this section

Genetic tests related to Melanoma:

id Genetic test Affiliating Genes
1 Malignant Melanoma25
2 Melanoma25

Anatomical Context for Melanoma

About this section

MalaCards organs/tissues related to Melanoma:

34
Skin, T cells, Brain, Lymph node, Lung, Liver, Breast

Animal Models for Melanoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Melanoma:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.9BRAF, CDKN2A, GPNMB, MITF, MLANA

Publications for Melanoma

About this section

Articles related to Melanoma:

(show top 50)    (show all 11533)
idTitleAuthorsYear
1
Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. (25169209)
2015
2
Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity. (25909885)
2015
3
Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis. (26539659)
2015
4
Vulvar melanoma with urethral invasion and bladder metastases - a case report and review of the literature. (25861315)
2015
5
Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor. (25614949)
2015
6
A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression. (25447045)
2015
7
Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass. (24999598)
2014
8
Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. (24482145)
2014
9
Radiation-inducible HtrA2 gene enhances radiosensitivity of uveal melanoma OCM-1 cells in vitro and in vivo. (24606398)
2014
10
Melanoma of the sellar region mimicking pituitary adenoma. (22624497)
2013
11
Xmrk-induced melanoma progression is affected by Sdf1 signals through Cxcr7. (24279354)
2013
12
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. (21317224)
2011
13
Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. (19421847)
2009
14
Novel therapeutics for melanoma. (19496721)
2009
15
Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. (18049450)
2008
16
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. (18523011)
2008
17
Genetic testing for melanoma predisposition: current challenges. (18025917)
2007
18
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. (16252259)
2006
19
Use of dynamic contrast-enhanced magnetic resonance imaging for differentiating between aggressive rectal tumours: two cases with small cell carcinoma and malignant melanoma. (17148806)
2006
20
A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma. (16121053)
2005
21
Validation of tissue microarray for the immunohistochemical profiling of melanoma. (15091192)
2004
22
A beneficial effect of a short-term formal training course in epiluminescence microscopy on the diagnostic performance of dermatologists about cutaneous malignant melanoma. (12877690)
2003
23
Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanoma. (12823444)
2003
24
Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). (12846571)
2003
25
Heterogeneous susceptibility to spontaneous and induced apoptosis characterizes two related transplantable melanomas with different biological properties. (12028588)
2002
26
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. (10967035)
2000
27
T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. (11041376)
2000
28
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. (11084335)
2000
29
Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. (10201537)
1999
30
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. (10594755)
1999
31
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. (10364001)
1999
32
Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study (COMS), Report no. 12, Part I. (10847038)
1999
33
Molecular genetics of familial cutaneous melanoma. (9469357)
1998
34
Development of targeted chemoradiotherapy for malignant melanoma by exploitation of metabolic pathway]. (9612704)
1998
35
P-selectin mediates adhesion of the human melanoma cell line NKI-4: identification of glycoprotein ligands. (9671523)
1998
36
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. (8826864)
1996
37
Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). (8740697)
1996
38
Transfection of human melanoma cells with type I interleukin-1 (IL-1) receptor cDNA rendered them IL-1-responsive and revealed the importance of ODC activity down-regulation in IL-1-induced growth inhibition. (8576096)
1995
39
Estramustine binding protein in primary tumours and metastases of malignant melanoma. (7703721)
1994
40
Acral lentiginous melanoma. (8328633)
1993
41
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. (8490900)
1993
42
Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2. (8260705)
1993
43
Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. (1629195)
1992
44
Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. (1671030)
1991
45
Effects of tumor promoters on adenylate cyclase activity in melanoma cells in culture. (2244938)
1990
46
Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines. (2829178)
1988
47
Paraneoplastic syndromes, tumor markers, and other unusual features of malignant melanoma. (2869074)
1986
48
Malignant melanomas causing Horner's syndrome in a horse. (3948837)
1986
49
Mycetoma pedis: report of a case clinically simulating malignant melanoma. (7108108)
1982
50
Osseous choristoma of the choroid simulating a choroidal melanoma. Association with a positive 32P test. (697626)
1978

Variations for Melanoma

About this section

Clinvar genetic disease variations for Melanoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1BRAFNM_004333.4(BRAF): c.1799T> A (p.Val600Glu)single nucleotide variantPathogenicrs113488022GRCh37Chr 7, 140453136: 140453136

Cosmic variations for Melanoma:

8 (show top 50)    (show all 176)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM584NRASskin,back,malignant melanoma,NSc.182A>Gp.Q61R0
2COSM476BRAFskin,NS,malignant melanoma,superficial spreadingc.1799T>Ap.V600E0
3COSM125734RAC1skin,NS,malignant melanoma,nodularc.85C>Tp.P29S0
4COSM580NRASskin,NS,malignant melanoma,superficial spreadingc.181C>Ap.Q61K0
5COSM553KRASskin,NS,malignant melanoma,nodularc.182A>Tp.Q61L0
6COSM583NRASskin,NS,malignant melanoma,nodularc.182A>Tp.Q61L0
7COSM585NRASskin,NS,malignant melanoma,nodularc.183A>Tp.Q61H0
8COSM5663CTNNB1skin,back,malignant melanoma,NSc.133T>Cp.S45P0
9COSM1119BRAFskin,NS,malignant melanoma,superficial spreadingc.1776A>Gp.I592M0
10COSM142241ADAMTS18skin,back,malignant melanoma,NSc.1969G>Ap.E657K0
11COSM21542BRAFskin,NS,malignant melanoma,superficial spreadingc.1813A>Gp.S605G0
12COSM564NRASskin,NS,malignant melanoma,nodularc.35G>Ap.G12D0
13COSM141946OR8B8skin,leg,malignant melanoma,NSc.361G>Ap.D121N0
14COSM577NRASskin,NS,malignant melanoma,superficial spreadingc.52G>Ap.A18T0
15COSM1116BRAFskin,NS,malignant melanoma,superficial spreadingc.1749T>Cp.F583F0
16COSM142304MMP24skin,leg,malignant melanoma,NSc.1519G>Ap.D507N0
17COSM483HRASskin,NS,malignant melanoma,superficial spreadingc.35G>Tp.G12V0
18COSM574NRASskin,leg,malignant melanoma,NSc.38G>Tp.G13V0
19COSM586NRASskin,NS,malignant melanoma,nodularc.183A>Cp.Q61H0
20COSM5610410PTPRKskin,back,malignant melanoma,NSc.3251+2T>Ap.?0
21COSM563NRASskin,NS,malignant melanoma,nodularc.34G>Ap.G12S0
22COSM231647PREX2skin,NS,malignant melanoma,nodularc.1994C>Tp.P665L0
23COSM573NRASskin,NS,malignant melanoma,superficial spreadingc.38G>Ap.G13D0
24COSM48298CDKN2Askin,back,malignant melanoma,NSc.301G>Tp.G101W0
25COSM107283PCDHB8skin,leg,malignant melanoma,NSc.931G>Ap.E311K0
26COSM141861ADGRL2skin,leg,malignant melanoma,NSc.1057T>Cp.Y353H0
27COSM131769ERBB4skin,back,malignant melanoma,NSc.1472G>Ap.R491K0
28COSM520KRASskin,NS,malignant melanoma,superficial spreadingc.35G>Tp.G12V0
29COSM581NRASskin,lower leg,malignant melanoma,nodularc.181C>Gp.Q61E0
30COSM235617MAP2K1skin,NS,malignant melanoma,nodularc.1144A>Cp.N382H0
31COSM107683FLT1skin,back,malignant melanoma,NSc.2827G>Ap.E943K0
32COSM231661PREX2skin,back,malignant melanoma,NSc.4066G>Ap.E1356K0
33COSM5608659ERBB4skin,back,malignant melanoma,NSc.1600G>Ap.E534K0
34COSM5608564EPHB4skin,back,malignant melanoma,NSc.2826C>Tp.I942I0
35COSM1290KITskin,back,malignant melanoma,NSc.1727T>Cp.L576P0
36COSM12503CDKN2Askin,NS,malignant melanoma,nodularc.334C>Gp.R112G0
37COSM1124BRAFskin,NS,malignant melanoma,superficial spreadingc.1791A>Gp.L597L0
38COSM5610538RPTORskin,back,malignant melanoma,NSc.484G>Ap.G162R0
39COSM231631PREX2skin,NS,malignant melanoma,nodularc.468G>Ap.K156K0
40COSM467BRAFskin,back,malignant melanoma,NSc.1781A>Gp.D594G0
41COSM1141BRAFskin,NS,malignant melanoma,nodularc.1846T>Cp.S616P0
42COSM231655PREX2skin,lower back,malignant melanoma,superficial spreadingc.2531G>Ap.G844D0
43COSM29844FGFR2skin,NS,malignant melanoma,superficial spreadingc.743T>Ap.V248D0
44COSM10656TP53skin,NS,malignant melanoma,superficial spreadingc.742C>Tp.R248W0
45COSM108917TMEM132Bskin,leg,malignant melanoma,NSc.2465G>Ap.G822E0
46COSM5609955PLCG1skin,back,malignant melanoma,NSc.1161G>Ap.K387K0
47COSM131751EPHB2skin,back,malignant melanoma,NSc.614C>Tp.A205V0
48COSM1140BRAFskin,NS,malignant melanoma,superficial spreadingc.1843G>Ap.G615R0
49COSM231663PREX2skin,lower back,malignant melanoma,superficial spreadingc.4165G>Ap.E1389K0
50COSM5049807NF1skin,NS,malignant melanoma,nodularc.3097C>Tp.Q1033*0

Copy number variations for Melanoma from CNVD:

6 (show top 50)    (show all 1973)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137911146500000InsertionMelanoma
213897110070601041599AmplificationC1orf159Melanoma
3149681111600000148000000DeletionMelanoma
4150081111800000116100000GainNRASMelanoma
5153871115048600115061038GainNRASMelanoma
6187151147200000149200000AmpficationSETDB1Melanoma
720086115300000247249719InsertionMelanoma
82128179207217092303813GainCDK6Malignant melanoma
9245431182188599196365692AmplificationASPMMelanoma
10245441182188599196365692AmplificationATP6V1G3Melanoma
11245451182188599196365692AmplificationB3GALT2Melanoma
12245461182188599196365692AmplificationC1orf27Melanoma
13245471182188599196365692AmplificationC1orf53Melanoma
14245481182188599196365692AmplificationC1orf99Melanoma
15245491182188599196365692AmplificationCDC73Melanoma
16245501182188599196365692AmplificationCFHMelanoma
17245511182188599196365692AmplificationCFHR1Melanoma
18245521182188599196365692AmplificationCFHR2Melanoma
19245531182188599196365692AmplificationCFHR3Melanoma
20245541182188599196365692AmplificationCFHR4Melanoma
21245551182188599196365692AmplificationCFHR5Melanoma
22245561182188599196365692AmplificationCRB1Melanoma
23245571182188599196365692AmplificationDENND1BMelanoma
24245581182188599196365692AmplificationF13BMelanoma
25245591182188599196365692AmplificationFAM5CMelanoma
26245601182188599196365692AmplificationGLRX2Melanoma
27245611182188599196365692AmplificationHMCN1Melanoma
28245621182188599196365692AmplificationKCNT2Melanoma
29245631182188599196365692AmplificationLHX9Melanoma
30245641182188599196365692AmplificationNEK7Melanoma
31245651182188599196365692AmplificationOCLMMelanoma
32245661182188599196365692AmplificationPDCMelanoma
33245671182188599196365692AmplificationPLA2G4AMelanoma
34245681182188599196365692AmplificationPRG4Melanoma
35245691182188599196365692AmplificationPTGS2Melanoma
36245701182188599196365692AmplificationPTPRCMelanoma
37245711182188599196365692AmplificationRGS1Melanoma
38245721182188599196365692AmplificationRGS13Melanoma
39245731182188599196365692AmplificationRGS18Melanoma
40245741182188599196365692AmplificationRGS2Melanoma
41245751182188599196365692AmplificationRGS21Melanoma
42245761182188599196365692AmplificationTPRMelanoma
43245771182188599196365692AmplificationTROVE2Melanoma
44245781182188599196365692AmplificationUCHL5Melanoma
45245791182188599196365692AmplificationZBTB41Melanoma
46262381198304656198310281DeletionMelanoma
47291721228366540228914590LOHMelanoma
48292951230000046500000InsertionMelanoma
49292961230000046500000InsertionMelanoma
50303061241700000247249719InsertionMelanoma

Expression for genes affiliated with Melanoma

About this section
Search GEO for disease gene expression data for Melanoma.

Pathways for genes affiliated with Melanoma

About this section

Pathways related to Melanoma according to KEGG:

32
id Name KEGG Source Accession
1Melanomahsa05218

Pathways related to Melanoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
110.1BRAF, CDKN2A, IL24

GO Terms for genes affiliated with Melanoma

About this section

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1signal transduction by p53 class mediatorGO:007233110.7MAGEA2, MAGEA2B
2negative regulation of protein acetylationGO:190198410.6MAGEA2, MAGEA2B
3negative regulation of protein sumoylationGO:003323410.4MAGEA2, MAGEA2B
4cellular senescenceGO:009039810.3CDKN2A, MAGEA2, MAGEA2B
5cellular protein catabolic processGO:004425710.2MAGEA2, MAGEA2B
6positive regulation of ubiquitin-protein transferase activityGO:00514439.9MAGEA2, MAGEA2B

Molecular functions related to Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1histone deacetylase bindingGO:004282610.1MAGEA1, MAGEA2, MAGEA2B

Sources for Melanoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet